Vichai Jirathitikal has developed an oral AIDS vaccine originally named V-1. V1 is a specially formulated pill that contains HIV-1 viral antigens capable of withstanding the degradation in the stomach. As a result V1 can pass into the gastrointestinal tract and will be eventually presented by intestinal enterocytes to underlying mucosal immune cells.
Bangkok, Thailand (PRWEB) September 29, 2007 -- Mr. Vichai Jirathitikal, a pharmacology graduate of Mahidol University, has developed an oral AIDS vaccine originally named V-1 or V1.V1 comprises pooled, inactivated HIV antigens derived from E and B clades of HIV-1 strain predominant in Thai population and is currently manufactured at a pharmaceutical plant owned by his family. The factory received GMP status form Thai FDA in July 2001. In contrast to other AIDS vaccines V1 is administered orally and not by injection.
V1 is a specially formulated pill that contains HIV-1 viral antigens capable of withstanding the degradation in the stomach. As a result V1 can pass into the gastrointestinal tract and will be eventually presented by intestinal enterocytes to underlying mucosal immune cells. The V1 is presented as 850mg pink-colored oval shaped pill. Vaccine is stable at ambient temperature for more than a year.
In the last few years Pharmacist Vichai has treated about 500 HIV-positive patients at his clinic in Bangpakong - a place located about 40 minutes drive from Bangkok City. When news of V1 therapy became known to the public the demand surged to unprecedented levels. Starting from June 2001 V1-Immunitor was distributed free of charge to about 40 thousand of HIV-infected individuals.The distribution was primarily sponsored by Immureboost Corporation.
V-1 is the most advanced product that has been used by over 66,000 thousand AIDS patients in more than 60 countries around the world. In a recent clinical study V-1 has normalized elevated liver enzymes in 95% of treated patients within one month, meaning that V-1 is potentially effective for hepatitis treatment (the article describing the clinical data was published in April, 2003 issue of Electronic Journal of Biotechnology - peer-reviewed journal sponsored by UNSECO). Considering that hepatitis is a poorly treatable disease that affects 500 million people, mostly in Asian countries, V-1 represents a considerable commercial value with return on investment potential vastly superior to AIDS, a disease which affects over 40 million people, most of whom are in low-income African countries.
V-1 was the first product developed by Mr. Vichai Jirathitikal. He now has other products of V-series which are all licensed by the Thai FDA as food supplements. V-2 is a broad spectrum anti-bacterial product, V-4 is anti-fungal product, and V-3 is an anti-cancer and is all available as pills. V-1 comprises pooled, inactivated HIV antigens derived from E and B clades of HIV-1 strain predominant in Thai population and is currently manufactured at a pharmaceutical plant owned by his family as an oral pill to be given to HIV-positive patients.
Situation in Thailand
Thailand has approximately one million people with HIV. While preventive measures established by the Government of Thailand are effective, the financial burden of caring for HIV/AIDS patients is beyond the budgetary means of the country, especially if 30 baht insurance program will be covering HIV-positive individuals. The Thai government is capable to provide free treatment for only 2,500 patients per year. The overwhelming majority of Thai HIV/AIDS patients have no access to antiretroviral drugs that have reduced death rates in Western countries. Antivirals even at subsidized prices are beyond of reach to ordinary Thais. At currently announced 1,800 baht (~$50US) per month the price of generic antiviral to be produced by the Government Pharmaceutical Organization of Thailand is still too high for most patients. Hospitals routinely send patients with terminal, full-blown AIDS to Buddhist temples to die. Unless something is done in expedite manner the situation in Thailand is extremely serious.
After more then ten years of intense laboratory studies and donating his time and money, Mr. Vichai Jirathitikal is now finalizing negotiations with a NASDAQ BB company who will make his dream come true. "Saving lives is so important Mr. Vichai exclaimed and we need money to build the laboratories for worldwide distribution of the V1 product". Immureboost (www.immureboost.com) has entered into an agreement with E savings store or (esav.ob) this company will help raise money to build manufacturing plants and labs globally to help people who are suffering from the HIV virus. Immureboost until several months ago was struggling until they hired a new consulting firm named e commerce energy (www.e-commerce-energy.com ) this company has helped them to develop their web site and connect them with different countries around the world so the V1 product would be exposed and recognized for a new miracle for people with AIDS.
###